Comment on "ALK is a therapeutic target for lethal sepsis"

Rafael B Blasco; Enrico Patrucco; Ines Mota; Wei-Tien Tai; Roberto Chiarle

doi:10.1126/scitranslmed.aar4321

Comment on "ALK is a therapeutic target for lethal sepsis"

Sci Transl Med. 2018 Dec 12;10(471):eaar4321. doi: 10.1126/scitranslmed.aar4321.

Authors

Rafael B Blasco¹, Enrico Patrucco², Ines Mota², Wei-Tien Tai¹, Roberto Chiarle^{3

2}

Affiliations

¹ Department of Pathology, Children's Hospital Boston and Harvard Medical School, Boston, MA 02115 USA.
² Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126 Italy.
³ Department of Pathology, Children's Hospital Boston and Harvard Medical School, Boston, MA 02115 USA. roberto.chiarle@childrens.harvard.edu.

Abstract

Physiologically relevant ALK (anaplastic lymphoma kinase) expression was not detected in human and mouse monocytes and macrophages, suggesting that the effects of bioactive compounds on stimulator of interferon genes (STING) activation may not depend on ALK.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anaplastic Lymphoma Kinase
Animals
Humans
Mice
Receptor Protein-Tyrosine Kinases*
Sepsis*

Substances

Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases

Grants and funding

R01 CA196703/CA/NCI NIH HHS/United States